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An update on molecular cat allergens: 
Fel d 1 and what else? Chapter 1: Fel d 1, the 
major cat allergen
B. Bonnet1,2†, K. Messaoudi3†, F. Jacomet4, E. Michaud5, J. L. Fauquert5, D. Caillaud6 and B. Evrard1,2* 
Abstract 
Background: Cats are the major source of indoor inhalant allergens after house dust mites. The global incidence of 
cat allergies is rising sharply, posing a major public health problem. Ten cat allergens have been identified. The major 
allergen responsible for symptoms is Fel d 1, a secretoglobin and not a lipocalin, making the cat a special case among 
mammals.
Main body: Given its clinical predominance, it is essential to have a good knowledge of this allergenic fraction, 
including its basic structure, to understand the new exciting diagnostic and therapeutic applications currently in 
development. The recent arrival of the component-resolved diagnosis, which uses molecular allergens, represents a 
unique opportunity to improve our understanding of the disease. Recombinant Fel d 1 is now available for in vitro 
diagnosis by the anti-Fel d 1 specific IgE assay. The first part of the review will seek to describe the recent advances 
related to Fel d 1 in terms of positive diagnosis and assessment of disease severity. In daily practice, anti-Fel d 1 IgE 
tend to replace those directed against the overall extract but is this attitude justified? We will look at the most recent 
arguments to try to answer this question. In parallel, a second revolution is taking place thanks to molecular engi-
neering, which has allowed the development of various forms of recombinant Fel d 1 and which seeks to modify the 
immunomodulatory properties of the molecule and thus the clinical history of the disease via various modalities of 
anti-Fel d 1-specific immunotherapy. We will endeavor to give a clear and practical overview of all these trends.
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Background
Worldwide, the domestic cat, Felis domesticus, is one of 
the most frequently encountered pets. It is a major source 
of allergens in the indoor environment and is placed in 
second position after dust mites for its involvement in 
the incidence of allergic respiratory diseases. In Western 
countries, the prevalence of sensitization to allergens of 
cat has increased dramatically to 10–30% in the general 
population [1]. A significant proportion of atopic sub-
jects (about 20–40%) are sensitized to cat allergens [2, 
3]. The severity of induced symptoms varies widely and 
cat allergy is thus a main risk factor of both rhinitis and 
asthma, including severe asthma, which can develop into 
a life-threatening condition.
Cat allergens have significant allergenicity. They are 
also numerous and cat allergen extracts are therefore a 
multi-allergenic source. Historically, 10 allergens recog-
nized by specific IgE have been identified in studies of 
extracts from fur, saliva, serum and urine [4, 5]. Eight cat 
allergens have been registered to date in the WHO/IUIS 
allergen nomenclature (Fel d 1 to Feld d 8). The develop-
ment of the component-resolved diagnosis (CRD), which 
uses molecular allergens produced by genetic engineer-
ing, offers new possibilities to improve the diagnosis and 
understanding of cat allergies [6]. The most important cat 
allergen in disease pathogenesis is, unlike in other mam-
mals, a secretoglobin, called Fel d 1, and not a lipocalin 
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[7]. Its predominance, shown by inhibition studies, is 
such that it is classically recognized as the major cat aller-
gen, the only one whose clinical impact is essential [8].
The aim of this first chapter is to review the basic 
knowledge of Fel d 1 and to give an update on new clini-
cal data, particularly the most recent clinical studies 
on the Fel d 1-based CRD of cat allergy and the various 
modalities of Fel d 1-specific immunotherapy.
Main text
Fel d 1, an uteroglobin‑like protein
Molecular characteristics
Fel d 1 is a glycoprotein of about 35–38  kDa [9, 10]. 
It consists of two identical heterodimers, each of 
18–19  kDa, linked noncovalently and eventually form-
ing a tetramer [10]. Each dimer consists of two poly-
peptide chains, chain 1 and chain 2, covalently linked 
by three disulfide bridges and encoded by two different 
genes [11, 12]. Chain 1 (or α) consists of 70 amino acids 
and has a molecular weight of 8  kDa. This polypeptide 
has a marked structural identity with the rabbit lipophi-
lin/secretoglobin (Ory c 3) and sequence homology with 
another member of the uteroglobin family, a protein of 
the human bronchial epithelial cells called Clara cell 
10-kDa protein [11, 13]. Chain 2 (or β) is a glycoprotein 
of 10 kDa with N-oligosaccharides. It consists of 85, 90 or 
92 amino acids [9]. Fel d 1 in its natural form is thought to 
be a mix of full and truncated forms of chain 2 [14]. The 
three-dimensional structure of Fel d 1 was determined, 
it is more complex than that of other allergens, with an 
internal cavity which could accommodate an endogenous 
ligand and two calcium external binding sites [9, 15, 16] 
(Fig. 1). Hence, the expression of recombinant Fel d 1 was 
more difficult to obtain than for other allergens. Each 
chain was first produced separately in simple systems 
using Escherichia coli (E. coli). However, to produce the 
full molecule rFel d 1, it was necessary to use a Baculo-
virus [14]. The advantage is that rFel d 1 is glycosylated 
(unlike products obtained via recombinant E. coli) and 
has a similar structure to that of the natural cat allergen 
nFel d 1 [14]. The epitopes of Fel d 1 are partially confor-
mational because the amount of IgE reactivity directed 
against each of the two chains of Fel d 1 separately is far 
less than that of total IgE reactivity against the natural 
heterodimer [17, 18].
Biological function, family
Fel d 1 belongs to the family of secretoglobins or secre-
tory globins [15]. The biological function of Fel d 1 is still 
unknown. It has been suggested that its role is to protect 
the skin, by homology with the uteroglobin whose func-
tion is to protect mucosa [19]. Other authors believe that 
Fel d 1 would rather have a role in the transport of lipid 
molecules, especially steroids, hormones or pheromones 
[20].
Epidemiology
Fel d 1 is a thermostable protein found in the saliva, anal 
glands, sebaceous glands, skin and fur of cats [11, 21, 22]. 
It is now recognized that the sebaceous glands, and not 
saliva, are the main production site [21–23].
All cats produce Fel d 1, but hormonal status modifies 
its production. For example, it has been shown that males 
produce more Fel d 1 than females [24]. In addition, cas-
trated male cats produce less Fel d 1 than non-castrated 
males [25]. Not all cats shed Fel d 1 in the air at the same 
rate [26]. Production of Fel d 1 on the skin varies accord-
ing to anatomical site and, for example, is much greater 
on the head than on the chest. The same distribution of 
Fel d 1 is found in the fur. The length of hair does not 
seem to affect the production of Fel d 1. Washing cats 
reduces the amount of Fel d 1 on the skin and fur but the 
effect does not last long as the amount of Fel d 1 returns 
to its original level in just 2 days [27, 28]. Similarly, the 
amount of Fel d 1 in ambient air is restored within 24 h 
[29]. Washing the cat is thus of little benefit.
In two large national surveys in the United States, Fel d 
1 was detected, respectively, in 99.9 and 99.7% of Ameri-
can homes [30, 31]. Fel d 1 was found in the dust of sofas, 
carpets and beds in homes with cats, but also in homes 
without a cat [30]. High levels of Fel d 1 were also found 
in the classroom, in cars, the offices of allergists, and 
shopping centers [32–34]. Fel d 1 allergen is ubiquitous. 
It is likely that it spreads from the clothes of cat owners 
and may also spread from their hair.
60% of airborne Fel d 1 is carried by small particles, 
of which 75% are more than 5 microns in diameter and 
25% less than 2.5 microns [35]. The immediate bronchial 
Fig. 1 Fel d 1 crystallographic structure highlighting the location 
of the calcium ions. From Ligabue-Braun et al. [16] reprints in open 
access
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response to Fel d 1 appears to be located in the proximal 
airways. The concentration of Fel d 1 required to induce a 
positive bronchial response in subjects with intermittent 
asthma was 20 times less when the allergen was carried 
by large particles (10.3 μm) than when Fel d 1 was carried 
by small particles (1.4 μm) [36]. However, a more recent 
article suggests that exposure under natural conditions 
to cat allergens (and not just to Fel d 1) induces a more 
peripheral airway obstruction [37].
Fel d 1 is easily airborne and remains in the indoor 
environment but the relationship between antigenic 
load and onset of symptoms is not as clear as with mite-
borne antigens [38]. There is still considerable difference 
of opinion on this subject. Several studies have reported 
a paradoxical effect of the presence of animals at home. 
While the presence of a cat in childhood seems to be a 
risk factor for sensitization and for developing asthma, 
children heavily exposed to a cat probably have a lower 
risk of developing a cat allergy [39–41]. Another large 
prospective study showed that living with a cat during 
childhood, especially during the first year of a child’s life, 
could be protective against allergic diseases [42]. Recent 
studies confirm these data, reporting that cat ownership 
during pregnancy and childhood in a large birth cohort 
(Avon Longitudinal Study of Parents and Children or 
ALSPAC) was consistently associated with a reduced risk 
of aeroallergen sensitization, wheezing and atopic asthma 
at the age of 7, but tended to be associated with an 
increased risk of non-atopic asthma [43, 44]. In another 
study, Carlsen’s team showed that the acquisition of a pet 
in early life did not appear to either increase or reduce the 
risk of asthma or allergic rhinitis symptoms in children 
aged 6–10 years [45]. Conversely, a recent French study 
(named PARIS) of 1860 infants reported that a cat enter-
ing the baby’s room in early life was strongly associated 
with aeroallergen sensitization (ORa 3.21, 95% CI 1.29–
8.01), particularly against Fe l d 1 [46]. An interesting 
explanation of these contradictory results could be found 
in the impact of pet allergen exposure during the neona-
tal period or early childhood on IgE trajectory develop-
ment, which can be modified by concomitant changes in 
microbial exposure (because of cesarean birth, for exam-
ple) [47]. Thus, changes in the environment, via modifica-
tions induced in the gut microbiota (because of different 
diets, for example), could have a significant impact on the 
protective effect or not of early exposure to pets and thus 
explain the disparities found in the different studies. It is 
interesting to note that these studies were not carried out 
in the same countries: for example, the studies of Collin 
et al. [43, 44] and Gabet et al. [46], which yielded contra-
dictory results, were respectively performed on children 
in the UK and in France, two countries with different eat-
ing habits. The role of these multiple interactions, such 
as exposure to allergens, intestinal microbiota and diet, 
need to be better understood and characterized.
CRD‑based clinical aspects
Allergenicity
Fel d 1 is the major allergen of domestic cats [7, 48, 49]. 
Anti-Fel d 1 specific IgE is found in the serum of more 
than 80–95% of patients allergic to cats [4, 5, 50, 51]. 
Crossed immunoelectrophoresis tests showed that most 
IgE antibodies to cat allergens in the serum of aller-
gic patients are directed against Fel d 1, and account 
for 60–90% of overall allergenic activity [4, 5, 11, 50, 
52]. In  vivo, the allergenicity of Fel d 1 is determined 
by its recognition by the mannose receptor on mucosal 
antigen-presenting cells, such as dendritic cells or mac-
rophages [53]. Several studies have shown that T cell 
response against Fel d 1 is polarized toward the Th2 path-
way [54–56].
Positive diagnostic value
The first clinical question regarding Fel d 1 is its place in 
the diagnostic strategy of cat allergy. Specifically, some 
authors question its ability to replace the overall extract 
in daily diagnostic practice, because theoretically, using 
anti-Fel d 1 specific IgE alone can lead to potential false 
negative results owing to the atypical profiles of sensitiza-
tion with IgE directed only against other cat allergens. A 
very recent study tried to provide an answer to this key 
point. Smoldovskaya et al. [57] compared in 139 patient 
serum samples the results of sensitization of the whole 
allergen extracts in relation to the recombinant pro-
tein in biochip-based immunoassay (EIMB RAS). They 
reported that values for diagnostic accuracy for the cat 
dander extract and its major recombinant component 
Fel d 1 were comparable, with similar ROC curves [57]. 
This suggests that the global extract could be replaced by 
the major allergen component Fel d 1 for diagnostic pur-
poses. Moreover, Asarnoj et al. [58], in the large BAMSE/
MeDALL study, showed that testing Fel d 1 sensitiza-
tion (analyzed with a chip based on ISAC Thermo Fis-
cher technology = Mechanisms for the Development of 
Allergy chip) was as good as testing for IgE to cat allergen 
extract (ImmunoCAP) and was more predictive of cat 
allergy at 16 years of age (Fig. 2).
Conversely, two new studies analyzing the usefulness 
of CRD analysis of cat allergy in routine clinical practice 
drew the exactly opposite conclusion [59, 60]. In the first, 
native cat extract serology testing was 100% successful 
in detecting patients who were allergic to cats but rFel d 
1 testing only 91% [59]. Thus, 9% of cat allergic patients 
would have not been detected with CRD testing alone. 
In the second, a substantial proportion (56/117; 48%) of 
subjects tested IgE positive for cat extracts (ImmunoCAP 
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IgE) were negative for all the corresponding cat compo-
nents (ImmunoCAP ISAC) including Fel d 1. However, as 
cat allergen components were not measured by unitary 
ImmunoCAP IgE, these results reflect probably more the 
lack of sensitivity of ISAC technology than of cat allergen 
components [60].
In another very recent study, of 70 pet allergic patients 
69 had positive cat skin prick tests and 65 were sensi-
tized to at least one feline component (Fel d 1, Fel d 2 
and Fel d 4). However, the IgE against cat global extract 
was not tested. Of the latter 65 patients, 61 were sensi-
tized against Fel d 1 (87.1% of the overall study group 
or 93.8% of patients having positive component-specific 
IgE), of whom 30 (46.2%) were monosensitized. Of the 65 
patients, 4 were sensitized only against Fel d 2 and/or Fel 
d 4 (6.1%) [61].
Finally, a synthesis of the recent literature on the bio-
logical diagnosis of cat allergy shows that the data from 
the studies are not always consistent. The analytical per-
formances of the anti-Fel d 1 specific IgE assay are close 
to those of the specific IgE assay directed against the 
overall extract. However, for a small number of cases 
with non-typical sensitization profiles (about 5–10%), the 
latter could have higher sensitivity. In our center, there-
fore, we consider that in the current state of knowledge 
an anti-overall extract specific IgE assay still has its place 
in daily practice in the positive diagnosis of cat allergy.
Assessment of the disease severity
The correlation between the level of Fel d 1-specific IgE 
and the severity of symptoms was assessed in a case–con-
trol study by ImmunoCap in 140 cat-allergic children and 
adults from Sweden and Austria suffering from asthma 
and/or rhinoconjunctivitis [48]. Positive IgE response to 
rFel d 1 was observed in 95.6% of cat-allergic children 
and in 94.4% of cat-allergic adults. The IgE levels in rFel 
d 1 among children with asthma were significantly higher 
than in children with rhinoconjunctivitis and adults 
with asthma. Increased Fel d 1-specific IgE levels could 
thus be a potential risk factor for allergic asthma in chil-
dren. In another recent study, IgE antibodies to Fel d 1 
were also associated with current asthma and showed a 
strong degree of correlation (r =  0.94) with cat dander 
titers, which were strongly associated with the preva-
lence, severity, and persistence of asthma in a 19-year-old 
population (ImmunoCAP 250) [62]. In the study of Pat-
elis, subjects sensitized to both cat extract and compo-
nents had higher FeNO (P = 0.008) and more bronchial 
responsiveness (P = 0.002) than subjects sensitized only 
to the extract [60]. Subjects sensitized to cat compo-
nents were more likely to develop asthma (P = 0.005) and 
rhinitis (P =  0.007) than subjects sensitized only to cat 
extract, which indicates the interest of CRD in cat allergy 
analysis, and in particular its value in testing the severity 
of the disease. An interesting study, comparing children 
with severe asthma (n = 37, age 13 years) and controlled 
asthmatics (n = 28, age 14 years) demonstrated that chil-
dren with severe asthma had higher levels of IgE antibod-
ies towards cat or Fel d 1 [63] (Fig. 3).
In addition, it has been shown that multi-sensitization 
towards more than three components including animal-
derived lipocalin, kallikrein and Fel d 1 was associated 
with cases of severe asthma and among which occurred 
increased bronchial inflammation and a trend towards 
more courses of oral corticosteroid treatment [64]. 
Another study involving 696 Swedish children reported 
that current asthma and asthma symptoms following 
contact with cats were associated with co-sensitization 
to Fel d 1 and Fel d 4 (tested with ImmunoCAP ISAC). 
Asthma was associated with higher levels of component 
sensitization (Fel d 1 ≥ 15 ISU), and sensitization to more 
than one component from the same animal conferred the 
greatest risk [65].
Thus, when all these data are compiled, it is clear that 
measuring anti-Fel d 1 specific IgE levels makes it pos-
sible to better evaluate the prognosis of cat allergy. The 
quantitative aspect of the assay is important since the 
highest levels will be correlated with the most severe 
forms of the disease. In daily practice in our hospital, we 
therefore perform anti-Feld 1 specific IgE assay as soon 
as it is necessary to evaluate the severity of cat allergy.
Use in specific immunotherapy
Allergen specific immunotherapy (AIT), consisting 
in progressive administration of increasing doses of 
Fig. 2 Specific IgE levels (≥ 0.3 ISU-E) to cat allergens in children with 
(white box plots) or without (gray box plots) symptoms to cat at 4, 8, 
and 16 years of age. From Asarnoj et al. [58] reprinted with permission 
from the publisher
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allergens by different delivery routes (mainly subcutane-
ous, sublingual or oral), results in long-term allergenic 
desensitization [66, 67]. Designed to modify the nature 
of the immune response against allergens and thus the 
history of the disease, it is currently the only treatment 
whose aim is not only symptomatic but also etiological 
[50].
In cat allergy, AIT was initially tested with cat dander 
extract, which was effective in the treatment of cat allergy 
symptoms, particularly respiratory symptoms. For exam-
ple, Alvarez-Cuesta et  al. [68], tested sublingual immu-
notherapy with an aqueous standardized semi-purified 
cat dander extract in a double blind placebo-controlled 
study. The results obtained showed that in the active 
group there was a significant reduction in symptoms dur-
ing the natural exposure challenge test. In addition, skin 
test reactivity to a standardized cat extract was better 
than in the placebo group [68]. However, the use of cat 
dander extract is constrained by different problems such 
as standardization, compliance and severe side effects 
[69].
For these reasons, and owing to its clinical predomi-
nance mentioned above, most studies now favor the use 
of Fel d 1 rather than global extract for cat allergy specific 
immunotherapy. Several molecular approaches using 
standardized preparations of Fel d 1 have been developed 
since the recombinant forms of this allergen have become 
available.
Hypoallergenic Fel d 1
To reduce the allergenicity of Fel d 1, and thus increase 
the security of AIT, various structural changes were 
made to Fel d 1. First, in order to modify the B cell 
epitopes, the disulfide bonds linking the Fel d 1 chains 
together were disrupted [70]. This leads to a decreased 
affinity of specific Fel d 1 IgE bound to the surface of 
mast cells and basophils on the FcɛRI receptor for Fel d 1. 
Seven candidates were thus generated and so designated 
hypoallergenic Fel d 1, owing to their ability to dimin-
ish IgE-binding and basophil activation [70]. In parallel, 
duplication of T-cell epitopes were added. Activation 
of T cells by these hypoallergenic Fel d 1 were thus not 
affected, or even increased, by this change in the struc-
ture [70]. More recently, seven recombinant mosaic pro-
teins were generated by reassembly of non-IgE-reactive 
peptides of Fel d 1 which contained the sequence ele-
ments for induction of allergen-specific blocking IgG 
antibodies and T cell epitopes [71]. Immunization of rab-
bits has showed that three constructs may be useful for 
vaccination and induction of blocking IgG antibodies and 
for tolerance induction.
T cell epitope‑containing peptides
In another approach based on the pivotal role of T cells 
in polarizing immune responsiveness to allergen, a team 
selected two peptides containing multiple T-cell epitopes 
from the sequence of Fel d 1. Unlike Fel d 1, these two 
peptides caused histamine release from basophils in < 1% 
of cat allergic patients and are unable to crosslink aller-
gen-specific IgE molecules on basophils in  vitro [72]. 
These peptides were then produced to obtain a peptide 
vaccine named Allervax  CAT®, which has been tested 
in clinical trials. Norman et  al. [72] conducted a study 
comparing a placebo group with three groups receiv-
ing Allervax  CAT® (7.5, 75 and 750 µg per dose) admin-
istered as a subcutaneous injection for 4  weeks. A high 
dose of Allervax  CAT® improved allergy symptoms after 
6  weeks of treatment [72]. However, the treatment was 
accompanied by side effects within minutes or hours 
after administration [73]. Thereafter, new Fel d 1 vaccines 
Fig. 3 Difference in bronchial responsiveness (lower values show more responsiveness, a) and % difference of fraction of exhaled nitric oxide 
(FeNO) (b) between subjects sensitized to cat extract or both extract and components vs. subjects not sensitized to cat. Results are from a multiple 
linear regression model and adjusted for age, BMI, sex, smoking at baseline. Reference group are the subjects negative to both extract and any cat 
component. From Patelis et al. [60] reprinted with permission from the publisher
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were generated, in particular one using 12 shorter syn-
thetic peptides, which reduced late-phase cutane-
ous reaction in a randomized double-blind controlled 
trial and late asthmatic reaction in another trial after 
3–4  months of treatment [55, 74]. From a mechanistic 
point of view, evidence has been provided that treatment 
with selected epitopes from Fel d 1 resulted in suppres-
sion of both human and murine responses unrestricted 
to these epitopes (namely associated with suppression of 
responses to other epitopes within the same molecule, 
called linked epitope suppression), together with sub-
stantial induction of IL-10 in murine T cells that was not 
limited to cells specific for the treatment peptide [75].
Another product for cat peptide immunotherapy was 
then developed and tested in allergic rhinoconjunctivi-
tis. This product, called Cat-PAD (Cat-peptide antigen 
desensitization), was the first in a new class of synthetic 
peptide immuno-regulatory epitopes (SPIREs). It consists 
of a mixture of seven small peptides derived from Fel d 1 
[76]. These peptides were selected to provide a similar T 
cell response to that generated by cat dander in ex vivo 
PBMC derived from cat-allergic patients [76]. Owing to 
their small size (13–17 amino acids), the peptides con-
stituting CAT-PAD cannot achieve cross-linking of IgE 
present on the surface of mast cells and basophils [76]. 
Clinical data from a series of randomized double-blind 
placebo-controlled studies confirm that Cat-PAD sig-
nificantly reduced allergic rhinoconjunctivitis symptoms. 
The effects lasted for 2 years after the initiation of treat-
ment [77, 78].
Recombinant fusion proteins
A third interesting approach consists in linking to Fel d 1 
another molecule that may have various immunological 
properties in order to target both effectors of innate or 
adaptive immunity. For example, the fusion protein H22-
Fel d 1, composed of rFel d 1 associated with a fragment 
of a humanized anti-CD64 antibody, has a high affinity 
for FcγRI, the high affinity IgG receptor, which is present 
on the surface of dendritic cells. In a monocyte-derived 
dendritic cell model, this resulted in increased uptake of 
Fel d 1. H22-Fel d 1 induced a semi-maturation of den-
dritic cells and led to a state of tolerance by promoting 
the secretion of cytokines such as IL-10 and IL-5 [79]. 
Another strategy was based on covalent linkage of Fel d 
1 to carbohydrate-based particles (CBP), i.e. agarose par-
ticles [80]. The objective was to enhance the amount of 
Fel d 1 at the particle surface to improve phagocytosis by 
antigen presenting cells to subsequently induce an immu-
nomodulatory effect on allergen-specific T cells. CBP-Fel 
d 1 was tested on a mouse model with cat allergy and the 
results obtained showed a reduction of airway inflam-
mation and decreased levels of Fel d 1-specific IgE [81]. 
Zhu et al. [82] designed and tested a chimeric human-cat 
fusion protein composed of Fcγ1, a truncated human IgG, 
and Fel d 1, in a new approach to allergy immunotherapy 
targeting FcγRIIb, the inhibitory receptor present on the 
surface of mast cells and basophils. This Fcγ-Fel d 1 pro-
tein induced as expected an allergen-specific inhibition 
of the degranulation of both types of cell [82]. Luzar et al. 
[83], developed a new hypoallergenic vaccine against cat 
Fig. 4 Possible mechanism of immune modulation in intralymphatic immunotherapy. From Kim et al. [87] reprints in open access
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allergy using mimotopes of the major cat allergen Fel d 
1 carried by bacteriophage particles. These bacteriophage 
constructs induced a predominant Th1 T cell response by 
promoting IL-2 production. There also exists a recombi-
nant fusion protein composed of non-allergenic Fel d 1 
peptides coupled with hepatitis B PreS protein [84].
Finally, the team of Senti produced MAT-Feld 1 (mod-
ular antigen transport-Fel d 1), fusing the recombinant 
allergen Fel d 1 with the TAT peptide derived from the 
HIV virus (MAT-Feld 1) [85]. They observed a significant 
decrease in nasal symptoms in patients who had received 
three intralymphatic injections of MAT-Fel d 1 compared 
to those in the placebo group. In addition, MAT-Fel d 1 
stimulated regulatory T cell response and increased the 
level of cat dander specific IgG4 [85, 86]. This raises the 
question of the route of administration. The form of AIT 
used in these latter works was intralymphatic immuno-
therapy (ILIT) [87] (Fig. 4). Subcutaneous immunother-
apy is a lengthy process requiring many administrations 
over a period of 3–5  years [85] and in addition entails 
various side effects [88]. The sublingual route is more 
comfortable for the patient but the treatment has to be 
administered more often. Against this background, the 
authors argue that ILIT is an interesting alternative that 
warrants testing. A recent study confirmed that ILIT can 
rapidly improve allergy symptoms and quality of life over 
a period of at least a year. However, the authors reported 
for the first time that, in hypersensitized patients, ILIT 
can cause severe systemic and/or local hypersensitiv-
ity reactions (when performed with aqueous allergen 
extracts) [89].
Conclusion
The appearance of the recombinant forms of Fel d 1 has 
led to the development of a CRD for cat allergy, which is 
very useful for the practitioner. Compared to the cat-spe-
cific IgE (whole extract), anti-Fel d 1 specific IgE have an 
equivalent or slightly lower sensitivity in terms of positive 
diagnosis and are correlated with disease severity and the 
risk of asthma occurrence. Molecular engineering has 
contributed to the emergence of multiple forms of Fel d 
1 specific immunotherapy that are still being improved to 
optimize the induction of a tolerogenic immune profile. 
They open up great therapeutic prospects for patients in 
the years to come. However, it is becoming clear that the 
multisensitized profiles correspond to particular pheno-
types of the disease, of more severe evolution. It is there-
fore important to carry out a complete evaluation of the 
cat molecular allergen, including minor fractions, to cor-
rectly characterize the patient profile, including the likely 
course of the disease, the potential cross-reactions and, 
finally, the expected immunotherapeutic response. We 
will deal with these aspects in the second part of this 
review, focusing on the less known molecular allergens of 
the cat, such as Fel d 2 or Fel d 4.
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